CA2554880A1 - Methods and compositions for modulating angiogenesis - Google Patents

Methods and compositions for modulating angiogenesis Download PDF

Info

Publication number
CA2554880A1
CA2554880A1 CA002554880A CA2554880A CA2554880A1 CA 2554880 A1 CA2554880 A1 CA 2554880A1 CA 002554880 A CA002554880 A CA 002554880A CA 2554880 A CA2554880 A CA 2554880A CA 2554880 A1 CA2554880 A1 CA 2554880A1
Authority
CA
Canada
Prior art keywords
ccx
agent
ckr2
cells
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002554880A
Other languages
English (en)
French (fr)
Inventor
Jennifer M. Burns
Bretton Summers
Yu Wang
Maureen Howard
Thomas Schall
Zhenhua Miao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2554880A1 publication Critical patent/CA2554880A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002554880A 2004-02-03 2005-02-02 Methods and compositions for modulating angiogenesis Abandoned CA2554880A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US54184904P 2004-02-03 2004-02-03
US60/541,849 2004-02-03
US59895804P 2004-08-04 2004-08-04
US60/598,958 2004-08-04
US62619504P 2004-11-08 2004-11-08
US60/626,195 2004-11-08
PCT/US2005/003521 WO2005074645A2 (en) 2004-02-03 2005-02-02 Methods and compositions for modulating angiogenesis

Publications (1)

Publication Number Publication Date
CA2554880A1 true CA2554880A1 (en) 2005-08-18

Family

ID=34841735

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002554880A Abandoned CA2554880A1 (en) 2004-02-03 2005-02-02 Methods and compositions for modulating angiogenesis

Country Status (7)

Country Link
US (1) US20050214287A1 (cg-RX-API-DMAC7.html)
EP (1) EP1715892A4 (cg-RX-API-DMAC7.html)
JP (1) JP4916889B2 (cg-RX-API-DMAC7.html)
AU (1) AU2005209921B2 (cg-RX-API-DMAC7.html)
CA (1) CA2554880A1 (cg-RX-API-DMAC7.html)
IL (1) IL177104A (cg-RX-API-DMAC7.html)
WO (1) WO2005074645A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038989A1 (en) * 2004-09-29 2006-04-13 Chemocentryx, Inc. Substituted arylamides
AU2006263657A1 (en) * 2005-06-29 2007-01-04 Chemocentryx, Inc. Substituted N-cinnamyl benzamides
US8088895B2 (en) * 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
JP2009091339A (ja) * 2007-10-12 2009-04-30 Seikagaku Kogyo Co Ltd 関節リウマチの処置剤
US8853202B2 (en) * 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
US20110014121A1 (en) * 2008-11-04 2011-01-20 Chemocentryx, Inc. Modulators of cxcr7
CA2742515C (en) * 2008-11-04 2017-07-11 Chemocentryx, Inc. 1,4-diazepane modulators of cxcr7
US20120045393A1 (en) 2009-03-17 2012-02-23 Linder Karen E Lhrh-ii peptide analogs
MX359651B (es) 2012-11-29 2018-10-05 Chemocentryx Inc Antagonistas de cxcr7.
MX2021006915A (es) 2018-12-12 2021-08-24 Chemocentryx Inc Inhibidores de cxcr7 para el tratamiento de cancer.
CN111593022B (zh) * 2018-12-27 2023-10-24 广州溯原生物科技股份有限公司 vMIP-Ⅱ诱导CD8+ T细胞去磷酸化为Tcm及其在药物中的应用
EP4326257A4 (en) 2021-04-19 2025-03-12 ChemoCentryx, Inc. AZETIDINYLACETAMIDES AS CXCR7 INHIBITORS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020166133A1 (en) * 1998-02-10 2002-11-07 Millennium Pharmaceuticals, Inc Neokine protein and nucleic acid molecules and uses therefor
JP2002506830A (ja) * 1998-03-13 2002-03-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療的ケモカイン受容体アンタゴニスト
US20020107195A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
DE60137435D1 (de) * 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
US20040157818A1 (en) * 2001-05-24 2004-08-12 Mikiro Yanaka Cxcr4-antagonistic drugs composed of nitrogen-containing compound
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
KR101061352B1 (ko) * 2002-12-20 2011-08-31 케모센트릭스 인간 종양-발현된 ｃｃｘｃｋｒ2의 저해물질
WO2004062591A2 (en) * 2003-01-06 2004-07-29 Oregon Health And Science University Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases

Also Published As

Publication number Publication date
IL177104A (en) 2010-12-30
WO2005074645A3 (en) 2005-12-22
JP2007520564A (ja) 2007-07-26
EP1715892A2 (en) 2006-11-02
AU2005209921B2 (en) 2011-04-07
US20050214287A1 (en) 2005-09-29
JP4916889B2 (ja) 2012-04-18
EP1715892A4 (en) 2008-07-09
WO2005074645A2 (en) 2005-08-18
AU2005209921A1 (en) 2005-08-18
IL177104A0 (en) 2006-12-10

Similar Documents

Publication Publication Date Title
JP4755107B2 (ja) ケモカイン受容体に関連する疾患および状態を検出および処置するための組成物および方法
AU2005209921B2 (en) Methods and compositions for modulating angiogenesis
KR20060136373A (ko) 케모카인 수용체와 관련된 질병 및 증상의 검출 및 치료용조성물 및 방법
IL175179A (en) A method of scanning for a factor that links ccx – ckr2 on a cell, and its use to detect the presence or absence of cancer
US20100247540A1 (en) Methods and Compositions For Modulating Angiogenesis
KR101149115B1 (ko) 혈관신생을 조절하기 위한 방법 및 조성물
MXPA06008680A (es) Metodos y composiciones para modular la angiogenesis
Lubberts et al. Requirement of IL-17 receptor signaling in resident synoviocytes for development of full blown destructive arthritis
HK1094203B (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
Mewar et al. Antibodies to ferritin in rheumatoid arthritis are associated with disease severity
Spachidou et al. Cultured salivary gland epithelial cells from patients with primary Sjögren's syndrome and disease controls are sensitive to signaling via Toll-like receptors 2 and 3: upregulation of intercellular adhesion molecule-1 expression
Adam et al. Toll-like receptor 4 polymorphisms and ankylosing spondylitis
Kinne et al. Cytokine expression was assessed during antigen-induced arthritis in the synovial membrane, inguinal lymph node, and spleen using competitive RT-PCR and sandwich ELISA
Timmer et al. Gene expression profiling provides a link between high inflammatory synovitis and myofibroblast-like synoviocytes
Dell'Accio et al. Molecular response to cartilage injury
Svenungsson et al. Endothelial function and activation in women with systemic lupus erythematosus
Fearon et al. Oncostatin M in rheumatoid arthritis: a key cytokine acts synergistically with other proinflammatory cytokines to promote human cartilage loss
Stummvoll et al. Autoreactive T cells to histone H1 and core histones in patients with systemic lupus erythematosus
Smith et al. Rheumatoid synovial fibroblasts activate endothelial cells and promote neutrophil recruitment in a flow based multicellular model of the rheumatoid pannus
Clavel et al. Kinetic and influence of angiogenesis in the course of collagen-induced arthritis
Palmer et al. Intracellular IL-1 receptor antagonist (icIL-1Ra1) does not antagonize growth inhibitory effects of pre-IL-1α in SaOS-2 cells
Ali et al. Complement and Fc receptor cross-talk in the Arthus reaction: the inflammatory cascade confirmed and refined
Bertsias et al. Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus
Ranganath Characteristics and outcomes in sero-positive late-onset rheumatoid arthritis patients who start a new disease modifying anti-rheumatic drug
Glocker et al. Molecular signatures of rheumatoid arthritis characterized by transcriptome and proteome analysis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130129